Abstract
AbstractT-cell therapy has emerged as transformative therapy for blood cancers. Autologous and allogeneic T-cells that have been genetically modified to express a chimeric antigen receptor, or CAR, have been shown to induce long-term remissions in patients with B-cell lymphoma, B-cell leukemia, and multiple myeloma. The delivery of cell-based therapies, whether autologous or allogeneic, is complex and requires collection, processing, and tracking systems that result in significant challenges to patients, their doctors, and the healthcare system. We will discuss the current clinical status of CAR T-cell therapies and important factors for physicians to consider in the long-term follow up of patients who have received any form of CAR T-cell or engineered T-cell therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
